Adults with asthma treated with add-on omalizumab report less limitation in activities of daily living

Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab

“…1 The management of dyspnoea is mainly based on bronchodilators and pulmonary rehabilitation in asthma and COPD with limited effects. In severe allergic asthma, omalizumab improves asthma symptoms, quality of life, reduces the risk of severe exacerbation and could also improve exertional dyspnoea 2 and exercise capacity judged by peak VO2. 3 In severe allergic asthma associated with COPD, retrospective studies also suggest that omalizumab could improve asthma control.…”